U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (date of earliest event reported):
July 10, 2013
Medisafe 1 Technologies Corp.
(Exact name of registrant as specified in
(State or other jurisdiction of incorporation)
|(Commission File No.)
||(IRS Employer Identification No.)|
c/o Jacob Elhadad
5A Hataltan Street
Jerusalem , Israel 96926
Phone Number 972-77-3318877
Fax number 972-77-3318879
(Address and telephone number of principal
executive offices and place of business)
(former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13ed-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 5 -- Corporate Governance and
Amendments to Articles of Incorporation or Bylaws, Change in Fiscal Year.
On or about September 30, 2011, the Company
received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing
in excess of 50.1 % of the total issued and outstanding shares of voting stock of the Company approving a Certificate of Amendment
to the Certificate of Incorporation of the Company, pursuant to which the Company will change , increase the authorized
capital of the Company to a total of 2,000,000,000 shares of common stock with a par value of $0.0001 per share.
The Company however only or about February
1 2013 , 2012, filed with the Secretary of the State of Delaware to amend the authorized capital of the Corporation to be 2,000,000,000 shares
of common stock, par value of $0.0001. The filing was initiated at this time, due to the necessity of the agreements
with Asher Enterprises and the associated convertible loans and convertible loan document requirements.
Pursuant to the requirements of the Securities
Exchange Act of 1934 the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 10,2013
||Medisafe 1 Technologies Corp.
Title: President and Director
(Principal Executive Officer)